March 05, 2026

Metformin’s Potential Role in PCO

Common diabetes therapy reaches intraocular lens tissue and may help limit posterior capsule opacification, says newly published data

Conexiant

February 23, 2026

Resveratrol and Diabetic Retinopathy

Could a multi-target molecule be used for earlier intervention of DR?

The Ophthalmologist

February 18, 2026

Can Diabetic Eye Testing Be Simplified?

Three-test models matched nine-test battery in classifying disease stages

Conexiant

February 17, 2026

Corneal Imaging and an ‘Overlooked Source’

Investigators evaluate how iris pigmentation influences Scheimpflug-derived corneal densitometry measurements.

Conexiant

February 16, 2026

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Conexiant

June 01, 2014

Indications and Considerations For Chromodissection

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

September 01, 2016

Innovation in Retina

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

October 01, 2016

CODING Q&A

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

May 23, 2025

Also in the News…

From new conferences and OCT systems to the links between pediatric uveitis and early-onset atopic dermatitis, these are the news stories and studies that caught our attention this week…

The Ophthalmologist